Biotech and Pharmaceutical Management Program
A new Biotech and Pharmaceutical Management Program has been launched by Cornell University‘s Jeb E. Brooks School of Public Policy in an effort to train the next generation of leaders in the quickly developing biotechnology and pharmaceutical industries.
The program’s objective is to introduce participants to the most recent business developments and cutting-edge research while also fostering peer networking and providing them with access to business leaders and esteemed university faculty.
“With insights from practitioners, policymakers and thought leaders, participants will gain real-world knowledge that can help shape their strategies and drive success in their organizations,” said Sean Nicholson, professor and director of the Sloan Program in Health Administration in the Brooks School.
“Through this program, we will broaden understanding of the shifts and issues in these sectors for a top-performing class of learners who can initiate industry-wide progress.”
The intensive program this year includes an immersive summit at Cornell Tech in New York City on September 29 and 30, as well as a live virtual course through eCornell from August 21 to September 25. To get the most out of the program, participants can choose to take both the virtual and in-person courses, or they can purchase them separately.
The summit at Cornell Tech will enable participants to engage with industry leaders and Cornell faculty in small panel discussions on topics such as the payer perspective, barriers and incentives for adoption, and diversity, equity, and inclusion in clinical trials. Among the featured speakers are:
• Bob Langer, academic cofounder at Moderna
• Angela Hwang, group president at Pfizer Biopharmaceuticals Group
• Amy Mulderry, chief development officer and CFO at Elevance Health
• Joydeep Ganguly, senior vice president at Gilead Sciences
• Arnaub Chatterjee, chief product and solutions officer at TriNetX
• Paul Evans, president and CEO at Velocity Clinical Research
In the online course, students will examine key management issues facing the pharma and biotech industries, navigate organizational silos and drug commercialization, evaluate lifecycle management and marketing strategies, discover how firms set prices and negotiate with insurers and analyze mergers and acquisitions.
Nicholson will guide the cohort through real-time discussions of current topics, including the role of biotech and genomics in transforming the industry, government regulation of the business, and tensions related to global product costs.
The Biotech and Pharmaceutical Management Program is available online for those who are interested in learning more about the business, economic, and policy issues that affect biopharma organizations.
Note: Content may be edited for style and length.
